RxLink will incorporate Cost Plus’ prices into its drug pricing platform MedMap.
Mark Cuban’s Cost Plus Drug Company continues to expand its partnerships.
RxLink announced that it will be incorporating Cost Plus into its platform.1 MedMap, RxLink’s platform, allows users to use their insurance, third-party discount cards, and manufacturer offers to find and compare drug prices. According to a press release, the addition of Cost Plus to the platform has already accounted for over $162,000 in savings for customers.
In a press release, RxLink’s head of strategic partnerships JB Powell said, “(The relationship is) a natural way for two organizations committed to ensuring access to safe, affordable medicines to work together. There has never been a solution that allows patients to easily understand exactly what their medications will cost before they go to the pharmacy. If we identify ways to reduce out-of-pocket costs, we connect the patient with them automatically; those options would be incomplete without including Cost Plus Drugs' low and transparent pricing. The added benefit is that by working with health systems and other digital health solutions, the savings are delivered by someone they can trust–their doctor."
In the same press release, Mark Cuban’s Cost Plus Drug Company CEO Alex Oshmyansky said, “We are excited to work with RxLink to bring lower prescription drug prices to consumers. Cost Plus Drugs and RxLink share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes."
This is just the latest partnership for Cost Plus. In early May of this year, ScionHealth announced that it would begin making bulk purchases of medications from Cost Plus and delivered to its SafeCor Health SafecorLogics program.2
Safecor Health provides unit-dose drug packing services for hospitals, long-term care providers, pharmaceutical manufacturers, and retail & digital health companies.
In a press release issued at the time, ScionHealth’s CEO Rob Jay said, “Across the industry and particularly in hospital settings, we are facing the challenges of rising drug and supply costs and navigating staffing shortages. ScionHealth is continually looking for innovative approach to address these issues while continuing to advance the delivery of high-quality, patient-centered care and wellbeing to our communities. SafecorLogics has already been an effective solution to help us address these challenges. Now, by introducing Cost Plus Drugs, we are confident we'll see even more success managing drug costs and enhancing care delivery across the ScionHealth network."
In April of this year, Price.com also announced a partnership with Cost Plus.3 As part of the partnership, Cost Plus’ pricing has been integrated into Price.com’s platform.
At the time, Oshmyanksky said in a press release, “We are thrilled to collaborate with Price.com in our mission to make prescription drugs more affordable for consumers. At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with Price.com, we are dedicated to providing affordable and accessible healthcare solutions for all."
Price.com founder and CEO RJ Jain added, “Teaming up with Mark Cuban Cost Plus Drug Company is a pivotal step towards achieving our shared goal of improving healthcare affordability and accessibility. Thanks to this collaboration, Price.com users can make informed choices that best suit their health and financial needs."
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.